Biomarkers of Inflammation and Fibrosis in Conduction Disorders After TAVI

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with severe aortic stenosis (a narrowed heart valve) who are having TAVI, a valve replacement through a tube. It studies blood markers taken before the procedure to predict heart rhythm conduction problems.

Életkor

18 Years and older

Nem

All

A betegség stádiuma

Severe aortic stenosis, diagnosed by current European Society of Cardiology (ESC) guidelines.

Korábbi kezelés

People who already had a permanent pacemaker, or a previous surgical or transcatheter aortic valve replacement, cannot join. People taking corticosteroids or other drugs that weaken the immune system cannot join.

A részvétel fő kizáró okai

• Acute infection, or chronic inflammatory or autoimmune disease
• Active cancer, or liver disease with poor liver function
• Heart attack or surgery within three months before the procedure
• End-stage chronic kidney disease (eGFR <15 ml/min)
• Permanent pacemaker or aortic valve replacement before

A regiszter feltételei, szó szerint

Mit akar kideríteni a vizsgálat

Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.

A vizsgálat 2 csoportja

• The group with new-onset TAVI-related conduction disorders (CDs)

  The group will include patients with new-onset CD or PPI detected during the index hospitalization and a 3-month follow-up period.

  Kezelés: Biomarkers of inflammation and fibrosis in pre-procedural serum blood samples és Transthoracic echocardiography with myocardial deformation analysis and staging according to the extent of cardiac damage related to AS

• The group without new-onset TAVI-related conduction disorders (CDs)

  The group will include patients without new-onset CD or PPI detected during the index hospitalization and a 3-month follow-up period.

  Kezelés: Biomarkers of inflammation and fibrosis in pre-procedural serum blood samples és Transthoracic echocardiography with myocardial deformation analysis and staging according to the extent of cardiac damage related to AS